Antibodies against antigens of hepatocyte cell membranes are formed in half the patients with hepatitis A and B in one-third of those with pseudotuberculosis. They occur in the period preceding the patients' convalescence rather than in the acute stage of the disease. The recovery of hepatitis patients in whom liver antibodies formed ensued significantly more rapidly than in persons with no autoantibodies. Antibodies against antigens of hepatocyte cell membranes were detectable in different clinical disease patterns. They did not influence the disease progress and witnessed hepatocyte injuries not only in the icteric but also in scarlatiniform and and abdominal disease patterns.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy.
Sci Rep
January 2025
Biological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, 10140, Thailand.
Nanobodies (Nbs) hold great potential to replace conventional antibodies in various biomedical applications. However, conventional methods for their discovery can be time-consuming and expensive. We have developed a reliable protein selection strategy that combines magnetic activated cell sorting (MACS)-based screening of yeast surface display (YSD) libraries and functional ligand-binding identification by Tat-based recognition of associating proteins (FLI-TRAP) to isolate antigen-specific Nbs from synthetic libraries.
View Article and Find Full Text PDFNeoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study.
Signal Transduct Target Ther
January 2025
Breast Center, The Second Hospital of Shandong University, Jinan, China.
The potential benefits of pyrotinib for patients with trastuzumab-insensitive, HER2-positive early-stage breast cancer remain unclear. This prospective, multicentre, response-adapted study evaluated the efficacy and safety of adding pyrotinib to the neoadjuvant treatment of HER2-positive breast cancer patients with a poor response to initial docetaxel plus carboplatin and trastuzumab (TCbH). Early response was assessed using magnetic resonance imaging (MRI) after two cycles of treatment.
View Article and Find Full Text PDFDiscussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy.
Hum Vaccin Immunother
December 2025
Department of Oncology, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
Human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such as trastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. This review examines the mechanisms of drug resistance in HER2-positive G/GEJ cancer, the primary mechanisms of resistance explored include alterations in the HER2 receptor itself, such as mutations and changes in expression levels, as well as downstream signaling pathways, and interactions with the tumor microenvironment (TME). Furthermore, the review discusses the Novel therapeutic approaches, including the use of antibody-drug conjugates (ADCs) and combination therapies are assessed for their potential to enhance outcomes.
View Article and Find Full Text PDFMicroneedle-delivered adeno-associated virus vaccine amplified anti-viral immunity by improving antigen-presenting cells infection.
J Control Release
January 2025
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Electronic address:
Adeno-associated viruses (AAV) have significant potential as vaccine carriers due to their excellent biosafety and efficient antigen gene delivery. However, most AAV vaccines show limited capacity to transduce antigen-presenting cells (APCs) following intramuscular injection which may cause inadequate cellular immune responses and undesired side effects due to transducing other tissues or cells. Herein, we developed a soluble microneedle patch for targeting the AAV vaccines to the epidermal and dermal APCs.
View Article and Find Full Text PDFDevelopment of a genetically modified full-length human respiratory syncytial virus preF protein vaccine.
Vaccine
January 2025
State Key Laboratory of Respiratory Diseases, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China. Electronic address:
Human Respiratory Syncytial Virus (hRSV) is a major cause of acute lower respiratory tract infections (ALRTI) in infants, the elderly, and immunocompromised individuals. The recent approval of recombinant protein-based hRSV vaccines represents significant progress in combating hRSV. However, these vaccines utilized optimized preF ectodomain attached with an exogenous trimeric motif, which may induce immunological complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!